AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
The global Immune Checkpoint Inhibitors Market is likely to witness a higher CAGR in the forecast period. Oncology is a wide field with various diagnoses and applications. Increase in cancer cases and...
Top Research Reports for JPMorgan, American Express & FedEx
Sector ETF report for PPH
Here are some reasons why investors may consider putting their money into Merck (MRK) stock.
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
The index advanced strongly this week before suffering a sharp decline on Thursday.
Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.
Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.
FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AstraZeneca PLC (NYSE:AZN),...
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.